UNITED STATES SECURITIES AND EXCHANGE COMMISSION  WASHINGTON, D.C. 20549  FORM 10-QSB/A  [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2001  [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from __________________ to __________________  Commission File Number 0-23957   MEDITECNIC,  INC. (Exact Name of small business issuer as specified in its charter)  Nevada 87-0430532 (State or other Jurisdiction of I.R.S. Employer Identi- Incorporation or Organization fication No.)  24351 Pasto Road, #B, Dana Point, California 92629 (Address of Principal Executive Offices) (Zip Code)  (949) 489-2400 (Issuer's Telephone Number, including Area Code)  Indicate by check mark whether the Registrant (i) has filed all reports required to be filed by Section 13, or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (of for such shorter period that the Registrant was required to file such reports) and (ii) has been subject to such filing requirements for the past 90 days.  YesNo X Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. YesNo __X__ Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.  Common Stock, par value  $.001 7,527,485 Title of Class Number of Shares outstanding at October 6, 2008 Transitional Small Business Format     Yes     No X       MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) BALANCE SHEET AS OF DECEMBER 31, 2000 AND SEPTEMBER 30, 2001  December 31 September 30 ASSETS 2000 2001  Current Assets Cash and Cash Equivalents $ 740,278 $ 284,708 Interest Receivable 4,855 4,856 Prepaid Expenses 11,356 11,356 Marketable Securities 766,990 731,290 Total Current Assets $ 1,523,479 $ 1,032,210  Other Assets Patents 761,620 872,326 Refundable Deposits 296,896 296,896 Total Other Assets 1,058,516 1,169,896  Total Assets $ 2,581,995 $ 2,201,432  LIABILIITES AND STOCKHOLDERS EQUITY Current Liabilities Accounts Payable -- 11,581 Total Current Liabilities -- 11,581  Stockholders Equity Preferred Stock (1,000 shares issued and outstanding) 1 1 Capital Stock (7,527,485 issued and outstanding) 7,528 7,528 Additional Paid In Capital 3,075,055 3,075,555 Accumulated Deficit During the Development Stage (282,748) (963,034) Accumulated Other Comprehensive Income 6,507 70,302 2,806,342 2,189,851  Total Liabilities and Stockholders Equity $ 2,806,342 $ 2,201,432          See accompanying Notes to Financial Statements.


MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) STATEMENTS OF OPERATIONS  CUMULATIVE FOR THE NINE FOR THE THREE FROM MONTHS ENDED MONTHS ENDED MARCH 24, 1998 SEPTEMBER 30 SEPTEMBER 30 SEPTEMBER 30 SEPTEMBER 30 TO Income 2001 2000 2001 2000 SEPTEMBER 30, 2001 Revenues $ -- $ -- $ -- $ -- $ -- Discounts Given to Customers -- -- -- -- -- Total Income -- -- -- -- --  Operating Expenses General and Administrative 7,241 4,500 (3,000) 1,500 93,270 Bank Charges 2,721 19,732 2,512 11,164 28,603 Patent Fees 66,798 12,680 28,027 9,576 79,480 Marketing and Advertising -- 656 -- -- 656 Translation Fees 846 1,377 -- -- 2,212 Other Financial Charges -- 43,440 -- 43,440 43,440 Legal and Accounting 160 3,130 -- 1,634 4,728 Travel Expenses 1,113 -- 1,113 -- 1,113 Research and Development 262,367 160,377 84,759 63,852 725,527 Audit Fees 5,000 3,816 -- 3,816 8,816 Total Operating Expenses 346,246 249,708 119,411 134,982 987,845  Net Operating Income (Loss) (346,246) (249,708) (119,411) (134,982) (987,845)  Other Income (Expense) Interest Income -- 20,456 -- 7,860 36,774 Interest Expense -- (4,772) -- (9) (7,301) Other Taxes (4,662) (4,772) -- (9) (4,662) Total Other Income (Expense) (4,662) 10,912 -- 7,842 24,811  Net Income (Loss) $ (350,908) $ (238,796) $ (119,411) $ (127,140) $ (963,034)  Other Comprehensive Income (Loss) Gain in Marketable Securities (35,700) 19,693 (21,980) 830 38,304 Exchange Adjustment (5,537) -- 112 -- 31,998 Net Other Comprehensive Income (Loss) (41,237) 19,693 (21,868) 830 70,302  Net Income (Loss) per share $ (0.0466) $ (0.0317) $ (0.0159) $ (0.0169) $ (0.1279)  See accompanying Notes to Financial Statements





MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) STATEMENT OF CASH FLOWS CUMULATIVE FOR THE NINE FOR THE THREE FROM MONTHS ENDED MONTHS ENDED MARCH 24, 1998 SEPTEMBER 30 SEPTEMBER 30 SEPTEMBER 30 SEPTEMBER 30 TO 2001 2000 2001 2000 SEPTEMBER 30, 2001 Net Income $ (350,908) $ (249,708) $ (119,411) $ (134,982) $ (963,034)  Adjustments to reconcile net income to net cash provided by operating activities Increase (decrease) in: Interest Receivable -- 4,742 -- -- (4,855) Prepaid Expenses -- -- -- -- (11,356) Decrease (increase) in: Accounts Payable 11,581 3,816 (5,328) 2,872 11,581 Other Comprehensive Income (41,237) 58,520 (21,868) 8,246 70,302 Net Cash Provided (Used) By Operating Activities (380,564) (182,630) (146,607) (123,864) (897,362)  CASH FLOWS FROM INVESTING ACTIVITIES  Cash Used for Deposit -- (62,830) -- -- (296,896) Cash Used of Patent Acquisition (110,706) (60,390) -- -- (872,326) (Increase) decrease in Marketable Securities 35,700 908,390 21,980 955,440 (731,264) Net Cash (Used) By Investing Activities (75,006) 785,169 21,980 955,440 (1,900,486)  Sale of Common Stock -- -- -- -- 3,082,556 Net Cash (Used) By Financing Activities -- -- -- -- 3,082,556  NET INCREASE (DECREASE) IN CASH (455,570) 602,539 (124,627) 831,576 284,708  CASH AT BEGINNING OF  PERIOD 740,278 267,820 409,335 38,783 --  CASH AT END OF PERIOD $ 284,708 $ 870,359 $ 284,708 $ 870,359 $ 284,708  Cash Paid for Interest -- -- -- -- 7,301         See accompanying Notes to Financial Statements.





MEDITECNIC, INC. (A Development Stage Company) NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) SEPTEMBER 30, 2001  Item 1. Comments  The accompanying financial statements are unaudited, but in the opinion of the management of the Company, contain all adjustments, consisting of only normal recurring accruals, necessary to present fairly the financial position at September 30, 2001, the results of operations for the three and nine months ended September 30, 2001 and 2000, and the cash flows for the three and nine months ended September 30, 2001 and 2000.  Reference is made to the Company's Form 10-KSB.  The results of operations for the three and nine months ended September 30, 2001 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2001.  Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION  The Company's research and development activities continued in the quarter and nine months ended September 30, 2001. Additional patents were purchased from Meditecnic SA, who performed research and development for the Company for consideration of $110,706.  Additional loans were made to Meditecnic SA of $121,409, $162,516 and $84,759 in the first, second and third quarters, respectively.  The Company realized a loss due to the decrease in market value of publicly traded securities it owns.  The Company has limited working capital and no income producing activities at this time.  PART II.  OTHER INFORMATION  Item 1. LEGAL PROCEEDINGS  -  None  Item 2. CHANGES IN SECURITIES - None  Item 3. DEFAULTS UPON SENIOR SECURITIES - None  Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - None  Item 5. OTHER INFORMATION - None  Item 6. EXHIBITS --None





SIGNATURES  Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.   MEDITECNIC, INC.    Date: October 6, 2008 By:/s/ Luc Badel Luc Badel Treasurer (chief financial officer and accounting officer and duly authorized officer)